Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 6, 2010, Pages 616-623

  Lim, Joanne Siok Liu ^a,b   Singh, Onkar ^a   Ramasamy, Rathi Devi ^a   Ramasamy, Saminathan ^a   Subramanian, Koilan ^a   Lee, Edmund J D ^b   Chowbay, Balram ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Asians; CYP1A2; Haplotypes; Linkage disequilibrium; Pharmacogenetics; Polymorphism

Indexed keywords

CYTOCHROME P450 1A2;

5' UNTRANSLATED REGION; ARTICLE; ASIAN; CHINESE; DNA POLYMORPHISM; ETHNIC DIFFERENCE; ETHNIC GROUP; EXON; GENE FREQUENCY; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; INDIAN; INTRON; MALAY; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; POPULATION RESEARCH; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78951493745     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-SC-051     Document Type: Article

References (29)

1. Zhou, S. F., Wang, B., Yang, L. P. and Liu, J. P.: Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab. Rev., 42: 268-354 (2010).
2. Schweikl, H., Taylor, J. A., Kitareewan, S., Linko, P., Nagorney, D. and Goldstein, J. A.: Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics, 3: 239-249 (1993).
3. Zhou, S. F., Chan, E., Zhou, Z. W., Xue, C. C., Lai, X. and Duan, W.: Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2. Curr. Drug Metab., 10: 713-729 (2009).
4. Gunes, A. and Dahl, M. L.: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 9: 625-637 (2008).
5. Rasmussen, B. B., Brix, T. H., Kyvik, K. O. and Brøsen, K.: The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics, 12: 473-478 (2002).
6. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee [Internet]. [updated 9-Sep-2008; cited 9-Dec-2009]. Available from: http://www.cypalleles.ki.se/
7. Zhou, S. F., Liu, J. P. and Chowbay, B.: Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev., 41: 89-295 (2009).
8. Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L. and Ingelman-Sundberg, M.: Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol., 64: 659-669 (2003).
9. Pavanello, S., Pulliero, A., Lupi, S., Gregorio, P. and Clonfero, E.: Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat. Res., 587: 59-66 (2005).
10. Sachse, C., Brockmöller, J., Bauer, S. and Roots, I.: Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 47: 445-449 (1999).
11. Nakajima, M., Yokoi, T., Mizutani, M., Kinoshita, M., Funayama, M. and Kamataki, T.: Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem., 125: 803-808 (1999).
12. Chen, X., Wang, L., Zhi, L., Zhou, G., Wang, H., Zhang, X., Hao, B., Zhu, Y., Cheng, Z. and He, F.: The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin. Pharmacol. Ther., 78: 249-259 (2005).
13. Gunes, A., Ozbey, G., Vural, E. H., Uluoglu, C., Scordo, M. G., Zengil, H. and Dahl, M. L.: Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics, 10: 769-778 (2009).
14. Woo, S.W., Kang, T. S., Park, H. J., Lee, J. E. and Roh, J.: Comparison of linkage disequilibrium patterns and haplotype structure of eight single nucleotide polymorphisms across the CYP1A2 gene between the Korean, and other populations registered in the International HapMap database. J. Clin. Pharm. Ther., 34: 429-436 (2009).
15. Barrett, J. C., Fry, B., Maller, J. and Daly, M. J.: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21: 263-265 (2005).
16. Han, X. M., Ouyang, D. S., Chen, X. P., Shu, Y., Jiang, C. H., Tan, Z. R. and Zhou, H. H.: Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J. Clin. Pharmacol., 54: 540-543 (2002).
17. Gemignani, F., Landi, S., Szeszenia-Dabrowska, N., Zaridze, D., Lissowska, J., Rudnai, P., Fabianova, E., Mates, D., Foretova, L., Janout, V., Bencko, V., Gaborieau, V., Gioia-Patricola, L., Bellini, I., Barale, R., Canzian, F., Hall, J., Boffetta, P., Hung, R. J. and Brennan, P.: Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis, 28: 1287-1293 (2007).
18. Bethke, L., Webb, E., Sellick, G., Rudd, M., Penegar, S., Withey, L., Qureshi, M. and Houlston, R.: Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer, 7: 123 (2007).
19. Prawan, A., Kukongviriyapan, V., Tassaneeyakul, W., Pairojkul, C. and Bhudhisawasdi, V.: Association between genetic polymorphisms of CYP1A2, arylamine N-acetyltransferase 1 and 2 and susceptibility to cholangiocarcinoma. Eur. J. Cancer Prev., 14: 245-250 (2005).
20. B'chir, F., Pavanello, S., Knani, J., Boughattas, S., Arnaud, M. J. and Saguem, S.: CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci., 84: 779-784 (2009).
21. Saebø, M., Skjelbred, C. F., Brekke Li, K., Bowitz Lothe, I. M., Hagen, P. C., Johnsen, E., Tveit, K. M. and Kure, E.H.: CYP1A2 164 A→C polymorphism, cigarette smoking, consumption of well-done red meat and risk of developing colorectal adenomas and carcinomas. Anticancer Res., 28: 2289-2295 (2008).
22. Altayli, E., Gunes, S., Yilmaz, A. F., Goktas, S. and Bek, Y.: CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int. Urol. Nephrol., 41: 259-266 (2009).
23. Ghotbi, R., Christensen, M., Roh, H. K., Ingelman-Sundberg, M., Aklillu, E. and Bertilsson, L.: Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotypephenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol., 63: 537-546 (2007).
24. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D. and Johnson, E. F.: Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem., 282: 14348-14355 (2007).
25. Zhou, H., Josephy, P. D., Kim, D. and Guengerich, F. P.: Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Biochem. Biophys., 422: 23-30 (2004).
26. Mestres, J.: Structure conservation in cytochromes P450. Proteins, 58: 596-609 (2005).
27. Lewis, D. F. V., Lake, B. G., Dickins, M., Ueng, Y. F. and Goldfarb, P. S.: Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure. Xenobiotica, 33: 239-254 (2003).
28. Bandelt, H. J., Forster, P. and Röhl, A.: Median-joining networks for inferring intraspecific phylogenies. Mol. Biol. Evol., 16: 37-48 (1999).
29. Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y. I., Kimura, H., Katoh, M., Sugai, K., Saitoh, O., Kawai, M., Ohnuma, T., Ohtsuki, T., Suzuki, C., Minami, N., Kamatani, N., Ozawa, S. and Sawada, J. I.: Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab. Pharmacokinet., 20: 24-33 (2005).